The Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center is pleased to announce the winners of our 7th annual Paper of the Year Award.
The best cost-effectiveness analysis published in 2024 was:
Brogan AJ, Davis AE, Mellott CE, Fraysse J, Metzner AA, Oglesby AK. Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States. Pharmacoeconomics. 2024 Apr;42(4):447-461. doi: 10.1007/s40273-023-01342-y.
This study assessed the lifetime cost-effectiveness of cabotegravir long-acting (CAB-LA), an injectable drug for pre-exposure prophylaxis (PrEP) against HIV, compared to generic oral PrEP in the United States. Using a Markov model, the researchers found that the CAB-LA treatment pathway was cost-effective versus generic oral PrEP, prevented 4.5 additional primary and secondary HIV-1 infections per 100 PrEP users, and resulted in 0.2 fewer quality-adjusted life years (QALYs) lost due to HIV. Results were consistent in “underserved populations with low oral PrEP usage.”
Brogan’s paper was chosen from a competitive pool of nominations for its novelty, implementation of real-world data, and exemplary use of health equity considerations in economic evaluations. Each paper underwent a blinded review by CEVR directors and faculty members, who evaluated the submissions for methodological quality, timeliness, and potential influence on policy or clinical decision-making. The top two papers with the highest faculty ratings were then reviewed by CEVR’s CEA Registry Scientific Advisory Board using the same criteria.
The runner-up for this category was:
- Nguyen TTH, Mital S. Cost-Effectiveness of Capivasertib as a Second-Line Therapy for Advanced Breast Cancer. Pharmacoeconomics. 2025 Mar;43(3):351-361. https://doi.org/10.1007/s40273-024-01456-x. Epub 2024 Dec 4.
CEVR is also thrilled to announce the winner of the Best CEA Registry Application category for our Paper of the Year awards.
In recognition of its outstanding importance, quality, and creativity, we selected the paper “Cost-effectiveness of interventions for HIV/AIDS, malaria, syphilis, and tuberculosis in 128 countries: a meta-regression analysis” as the winner.
Written by Fiona Silke et al. and published in The Lancet Global Health, this article addresses the lack of country-specific CEAs for interventions for HIV/AIDS, malaria, syphilis, and tuberculosis. The authors conducted a meta-regression of available CEAs from the CEA Registry to predict incremental cost-effectiveness ratios (ICERs) for 14 recommended interventions in individual countries. The findings provide valuable information to help decision makers allocate limited resources toward interventions that will provide the largest population health benefits.
